FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3090081825> ?p ?o ?g. }

• W3090081825 abstract "Abstract Background Whether sodium glucose co-transporter 2 inhibitors (SGLT2i) are associated with a lower risk of cardiovascular as well as adverse lower limb events in patients with type-2 diabetes mellitus (T2DM) and concomitant peripheral artery disease (PAD) is unclear. We aimed to evaluate the risk of cardiovascular and limb events, and death associated with the use of SGLT2i compared with dipeptidyl peptidase-4 inhibitors (DPP4i) among a longitudinal and national cohort of patients with T2DM. Methods In this nationwide retrospective cohort study based on the Taiwan National Health Insurance Research Database, we identified a total of 11,431 and 93,972 consecutive T2DM patients with PAD taking SGLT2i and DPP4i, respectively, from May 1, 2016, to December 31, 2017. We used 1:1 propensity score matching (PSM) to balance covariates across study groups. Patients were followed from the drug index date until the occurrence of clinical outcomes, death, discontinuation of the index drug, or the end of the study period, whichever occurred first. Results Overall, 56% and 44% of the patients were treated with dapagliflozin and empagliflozin, respectively. The use of SGLT2i had comparable risks of ischemic stroke and acute myocardial infarction, and was associated with lower risks of congestive heart failure (CHF) [hazard ratio (HR): 0.66; 95% confidence interval (CI) 0.49–0.89; p = 0.0062], lower limb ischemia requiring revascularization (HR: 0.73; 95% CI 0.54–0.98; p = 0.0367) or amputation (HR: 0.43; 95% CI 0.30–0.62; p < 0.0001), and cardiovascular death (HR: 0.67; 95% CI 0.49–0.90; p = 0.0089) when compared with the DDP4i group after PSM. The subgroup analysis revealed consistent results for CHF and major adverse limb outcomes for SGLT2i versus DPP4i among patients aged ≥ 75 years, the presence of chronic kidney disease and established cardiovascular disease was consistent with the main analysis. Conclusions SGLT2i were associated with lower risks of CHF and adverse lower limb events compared with DPP4i among patients with T2DM and PAD in real-world practice." @default.
• W3090081825 created "2020-10-08" @default.
• W3090081825 creator A5002654282 @default.
• W3090081825 creator A5025361204 @default.
• W3090081825 creator A5028640531 @default.
• W3090081825 creator A5049753044 @default.
• W3090081825 creator A5052425370 @default.
• W3090081825 creator A5054836375 @default.
• W3090081825 creator A5062403345 @default.
• W3090081825 creator A5069412202 @default.
• W3090081825 creator A5072714961 @default.
• W3090081825 creator A5073045264 @default.
• W3090081825 date "2020-09-30" @default.
• W3090081825 modified "2023-10-17" @default.
• W3090081825 title "Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor" @default.
• W3090081825 cites W2013047715 @default.
• W3090081825 cites W2014179250 @default.
• W3090081825 cites W2019200806 @default.
• W3090081825 cites W2034942998 @default.
• W3090081825 cites W2036193982 @default.
• W3090081825 cites W2048470090 @default.
• W3090081825 cites W2064130493 @default.
• W3090081825 cites W2075347392 @default.
• W3090081825 cites W2087477127 @default.
• W3090081825 cites W2114261707 @default.
• W3090081825 cites W2124658554 @default.
• W3090081825 cites W2126049444 @default.
• W3090081825 cites W2127854619 @default.
• W3090081825 cites W2142830692 @default.
• W3090081825 cites W2144168223 @default.
• W3090081825 cites W2146264128 @default.
• W3090081825 cites W2159352081 @default.
• W3090081825 cites W2520126873 @default.
• W3090081825 cites W2626446274 @default.
• W3090081825 cites W2756318809 @default.
• W3090081825 cites W2761300231 @default.
• W3090081825 cites W2768451744 @default.
• W3090081825 cites W2770821084 @default.
• W3090081825 cites W2780645176 @default.
• W3090081825 cites W2793906475 @default.
• W3090081825 cites W2794833267 @default.
• W3090081825 cites W2808939545 @default.
• W3090081825 cites W2810587401 @default.
• W3090081825 cites W2832569129 @default.
• W3090081825 cites W2886009800 @default.
• W3090081825 cites W2894993577 @default.
• W3090081825 cites W2899764361 @default.
• W3090081825 cites W2900413769 @default.
• W3090081825 cites W2965578843 @default.
• W3090081825 cites W2970848622 @default.
• W3090081825 cites W2971147579 @default.
• W3090081825 cites W2973090108 @default.
• W3090081825 cites W2974260792 @default.
• W3090081825 cites W2976129020 @default.
• W3090081825 cites W2978398047 @default.
• W3090081825 cites W3004109662 @default.
• W3090081825 cites W3033374042 @default.
• W3090081825 cites W4243204328 @default.
• W3090081825 doi "https://doi.org/10.1186/s12933-020-01118-0" @default.
• W3090081825 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7528264" @default.
• W3090081825 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32998736" @default.
• W3090081825 hasPublicationYear "2020" @default.
• W3090081825 type Work @default.
• W3090081825 sameAs 3090081825 @default.
• W3090081825 citedByCount "20" @default.
• W3090081825 countsByYear W30900818252021 @default.
• W3090081825 countsByYear W30900818252022 @default.
• W3090081825 countsByYear W30900818252023 @default.
• W3090081825 crossrefType "journal-article" @default.
• W3090081825 hasAuthorship W3090081825A5002654282 @default.
• W3090081825 hasAuthorship W3090081825A5025361204 @default.
• W3090081825 hasAuthorship W3090081825A5028640531 @default.
• W3090081825 hasAuthorship W3090081825A5049753044 @default.
• W3090081825 hasAuthorship W3090081825A5052425370 @default.
• W3090081825 hasAuthorship W3090081825A5054836375 @default.
• W3090081825 hasAuthorship W3090081825A5062403345 @default.
• W3090081825 hasAuthorship W3090081825A5069412202 @default.
• W3090081825 hasAuthorship W3090081825A5072714961 @default.
• W3090081825 hasAuthorship W3090081825A5073045264 @default.
• W3090081825 hasBestOaLocation W30900818251 @default.
• W3090081825 hasConcept C126322002 @default.
• W3090081825 hasConcept C127413603 @default.
• W3090081825 hasConcept C134018914 @default.
• W3090081825 hasConcept C141071460 @default.
• W3090081825 hasConcept C167135981 @default.
• W3090081825 hasConcept C17923572 @default.
• W3090081825 hasConcept C197934379 @default.
• W3090081825 hasConcept C207103383 @default.
• W3090081825 hasConcept C2775887513 @default.
• W3090081825 hasConcept C2777422806 @default.
• W3090081825 hasConcept C2778715236 @default.
• W3090081825 hasConcept C2778763485 @default.
• W3090081825 hasConcept C2779384505 @default.
• W3090081825 hasConcept C2779668873 @default.
• W3090081825 hasConcept C2780645631 @default.
• W3090081825 hasConcept C2910068830 @default.
• W3090081825 hasConcept C44249647 @default.
• W3090081825 hasConcept C500558357 @default.
• W3090081825 hasConcept C555293320 @default.
• W3090081825 hasConcept C71924100 @default.

• next